These results are consistent with prior studies that have shown superior efficacy of HER2-targeted therapies in HER2-positive breast cancer, likely attributable to higher HER2 expression levels, which enhance ADCs binding and internalization [13,16]. This evidence concerns the gene ERBB2 and breast carcinoma.